JP2006514098A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514098A5
JP2006514098A5 JP2005501406A JP2005501406A JP2006514098A5 JP 2006514098 A5 JP2006514098 A5 JP 2006514098A5 JP 2005501406 A JP2005501406 A JP 2005501406A JP 2005501406 A JP2005501406 A JP 2005501406A JP 2006514098 A5 JP2006514098 A5 JP 2006514098A5
Authority
JP
Japan
Prior art keywords
compound according
androgen receptor
receptor modulator
structural formula
following chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005501406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514098A (ja
JP4764719B2 (ja
Filing date
Publication date
Priority claimed from US10/270,732 external-priority patent/US6998500B2/en
Priority claimed from US10/371,213 external-priority patent/US7026500B2/en
Application filed filed Critical
Publication of JP2006514098A publication Critical patent/JP2006514098A/ja
Publication of JP2006514098A5 publication Critical patent/JP2006514098A5/ja
Application granted granted Critical
Publication of JP4764719B2 publication Critical patent/JP4764719B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005501406A 2002-10-16 2003-10-14 ハロゲン化選択的アンドロゲン受容体調節剤及びその使用方法 Expired - Fee Related JP4764719B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/270,732 2002-10-16
US10/270,732 US6998500B2 (en) 2000-08-24 2002-10-16 Selective androgen receptor modulators and methods of use thereof
US10/371,213 2003-02-24
US10/371,213 US7026500B2 (en) 2000-08-24 2003-02-24 Halogenated selective androgen receptor modulators and methods of use thereof
PCT/US2003/032507 WO2004035736A2 (en) 2002-10-16 2003-10-14 Halogenated selective androgen receptor modulators and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2006060868A Division JP2006199704A (ja) 2002-10-16 2006-03-07 選択的アンドロゲン受容体調節剤及びその使用方法
JP2007121464A Division JP4694529B2 (ja) 2002-10-16 2007-05-02 選択的アンドロゲン受容体調節剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2006514098A JP2006514098A (ja) 2006-04-27
JP2006514098A5 true JP2006514098A5 (enExample) 2006-08-17
JP4764719B2 JP4764719B2 (ja) 2011-09-07

Family

ID=32109809

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2005501406A Expired - Fee Related JP4764719B2 (ja) 2002-10-16 2003-10-14 ハロゲン化選択的アンドロゲン受容体調節剤及びその使用方法
JP2006060868A Pending JP2006199704A (ja) 2002-10-16 2006-03-07 選択的アンドロゲン受容体調節剤及びその使用方法
JP2007121464A Expired - Fee Related JP4694529B2 (ja) 2002-10-16 2007-05-02 選択的アンドロゲン受容体調節剤及びその使用方法
JP2010282886A Pending JP2011052027A (ja) 2002-10-16 2010-12-20 選択的アンドロゲン受容体調節剤及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006060868A Pending JP2006199704A (ja) 2002-10-16 2006-03-07 選択的アンドロゲン受容体調節剤及びその使用方法
JP2007121464A Expired - Fee Related JP4694529B2 (ja) 2002-10-16 2007-05-02 選択的アンドロゲン受容体調節剤及びその使用方法
JP2010282886A Pending JP2011052027A (ja) 2002-10-16 2010-12-20 選択的アンドロゲン受容体調節剤及びその使用方法

Country Status (22)

Country Link
US (1) US7026500B2 (enExample)
EP (3) EP1764357A1 (enExample)
JP (4) JP4764719B2 (enExample)
KR (3) KR101107031B1 (enExample)
CN (3) CN101062023A (enExample)
AT (1) ATE430125T1 (enExample)
AU (1) AU2003287074B2 (enExample)
BR (1) BR0314891A (enExample)
CA (3) CA2502355A1 (enExample)
CY (1) CY1109858T1 (enExample)
DE (1) DE60327456D1 (enExample)
DK (1) DK1558565T3 (enExample)
EA (2) EA011744B1 (enExample)
ES (1) ES2324606T3 (enExample)
GE (2) GEP20084434B (enExample)
HR (2) HRP20070457A2 (enExample)
IL (2) IL182880A0 (enExample)
MX (1) MXPA05004076A (enExample)
PT (1) PT1558565E (enExample)
SI (1) SI1558565T1 (enExample)
TW (1) TWI332955B (enExample)
WO (1) WO2004035736A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) * 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20030232792A1 (en) * 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
DK1463497T3 (da) * 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
AU2003287077B2 (en) * 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
CA2501874A1 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JP4603528B2 (ja) * 2003-01-13 2010-12-22 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体の大規模合成
WO2004064747A2 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
AU2004281708B2 (en) * 2003-10-14 2011-02-17 University Of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
CA2522874A1 (en) * 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
DK2289872T3 (en) * 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP5215300B2 (ja) * 2006-07-12 2013-06-19 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
BRPI0714526A2 (pt) * 2006-08-24 2013-04-30 Univ Tennessee Res Foundation acilanilidas substituÍdas e seus mÉtodos de uso
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
AR067823A1 (es) 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica
AU2008298901C1 (en) * 2007-09-11 2013-10-03 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
CN105664136A (zh) 2008-05-07 2016-06-15 加利福尼亚大学董事会 眼表润滑的治疗性补充和富集
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US20110223201A1 (en) * 2009-04-21 2011-09-15 Selecta Biosciences, Inc. Immunonanotherapeutics Providing a Th1-Biased Response
CN103002737A (zh) * 2010-01-11 2013-03-27 Gtx公司 治疗睑板腺功能障碍的方法
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
CN110840870A (zh) 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
RU2483742C1 (ru) * 2012-07-18 2013-06-10 Татьяна Владимировна Буткова Способ лечения расстройств эрекции и расстройств полового влечения
MX374840B (es) * 2013-12-23 2025-03-06 Bcn Peptides Sa Analogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acumulo lisosomal o glucogenosis.
US10441567B2 (en) * 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
RU2577225C1 (ru) * 2015-03-27 2016-03-10 Общество С Ограниченной Ответственностью "Парафарм" Препарат и способ для лечения дефицита андрогенов у женщин, содержащий энтомологические протеины
RU2620020C2 (ru) * 2015-10-06 2017-05-22 Рустем Фрунзевич Байкеев Способ идентификации сексуального статуса женщины с сексуальным либидо
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
CA3133929A1 (en) 2019-04-19 2020-10-22 Lin Zhi Crystalline forms and methods of producing crystalline forms of a compound
MX2021013774A (es) * 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN116348142A (zh) 2020-10-08 2023-06-27 塔尔格免疫治疗有限公司 用于治疗癌症的免疫疗法
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3237153A1 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
EP4615511A1 (en) 2022-11-07 2025-09-17 TargImmune Therapeutics AG Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
AU2023376540A1 (en) 2022-11-07 2025-05-15 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE9217131U1 (de) * 1992-12-08 1993-03-11 Chr. Berghöfer GmbH & Co. KG, 3500 Kassel Armatur für einen Schlauch oder ein flexibles Rohr mit einer profilierten Außenfläche
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6492554B2 (en) * 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
US6019957A (en) * 1997-06-04 2000-02-01 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US6795776B1 (en) 1999-10-14 2004-09-21 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
IL149056A0 (en) 1999-10-19 2002-11-10 Nobex Corp Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
NZ518552A (en) 1999-10-27 2003-10-31 Nobex Corp Resolution of intermediates in the synthesis of substantially pure bicalutamide
EP1118811A3 (de) * 2000-01-19 2003-05-21 Witzenmann GmbH Flexibles Leitungselement mit einer an mindestens einem Ende angebrachten Anschlussvorrichtung
CA2413417A1 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
CA2420279C (en) 2000-08-24 2011-07-19 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DK1463497T3 (da) * 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
HRP20100067A2 (hr) * 2002-02-07 2010-04-30 University Of Tennessee Research Foundation Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2006514098A5 (enExample)
JP2006518328A5 (enExample)
JP2006506369A5 (enExample)
JP2005526741A5 (enExample)
JP2006511486A5 (enExample)
JP6434482B2 (ja) 置換アシルアニリドおよびそれらの使用方法
JP2009506119A5 (enExample)
ES2784454T3 (es) Aril éteres y usos de los mismos
JP2019517487A5 (enExample)
JP2011500621A5 (enExample)
JP2010509356A5 (enExample)
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
JP2013532652A5 (enExample)
CA2621189A1 (en) Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
JP2013545785A5 (enExample)
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2010512419A (ja) 医薬組成物およびそれの使用方法
RU2013156361A (ru) Новые соединения
TW201333012A (zh) 咪唑并吡咯啶酮化合物
JP2013056886A5 (enExample)
JP2009513703A5 (enExample)
JP2008540554A5 (enExample)
KR20140022873A (ko) 당뇨병을 치료하기 위한 선택적인 안드로겐 수용체 모듈레이터
JP2014037426A5 (enExample)
JP2007507494A5 (enExample)